Liu YM

References (14)

Title : Isosteroidal alkaloids of Fritillaria taipaiensis and their implication to Alzheimer's disease: Isolation, structural elucidation and biological activity - Wang_2022_Phytochemistry__113279
Author(s) : Wang AW , Liu YM , Zhu MM , Ma RX
Ref : Phytochemistry , :113279 , 2022
Abstract : Four undescribed and five known isosteroidal alkaloids were isolated from the bulbs of Fritillaria taipaiensis and their structures were elucidated on the basis of HR-ESI-MS, 1D and 2D NMR spectroscopic data analyses. The undescribed compounds were designated taipainines A-D. Of these, taipainine D presented a unique structure having the D/E trans (H-13alpha/H-17beta) and E/F cis (beta-axial lone pair of the N atom/H-22beta) ring junctions. Possible biosynthetic pathway to taipainine D is proposed. Four compounds showed significant BChE inhibitory activities similar or better than the positive control galantamine. In addition, the preliminary structure-activity relationships (SARs) of these isosteroidal alkaloids were also investigated.
ESTHER : Wang_2022_Phytochemistry__113279
PubMedSearch : Wang_2022_Phytochemistry__113279
PubMedID: 35728673

Title : Discovery of Guanidine Derivatives from Buthus martensii Karsch with Metal-Binding and Cholinesterase Inhibition Properties - Liu_2021_Molecules_26_
Author(s) : Liu YM , Fan JJ , Wang LN
Ref : Molecules , 26 : , 2021
Abstract : Two rare guanidine-type alkaloids, Buthutin A (1) and Buthutin B (2), along with two other compounds (3, 4), were isolated from Buthus martensii Karsch, and determined using extensive spectroscopic data analysis and high resolution-mass spectrometry. Compound 1 showed the most potent inhibition on AChE and BChE with IC(50) values of 7.83 +/- 0.06 and 47.44 +/- 0.95 microM, respectively. Kinetic characterization of compound 1 confirmed a mixed-type of AChE inhibition mechanism in accordance with the docking results, which shows its interaction with both catalytic active (CAS) and peripheral anionic (PAS) sites. The specific binding of compound 1 to PAS domain of AChE was also confirmed experimentally. Moreover, compounds 1 and 3 exhibited satisfactory biometal binding abilities toward Cu(2+), Fe(2+), Zn(2+) and Al(3+) ions. These results provide a new evidence for further development and utilization of B. martensii in health and pharmaceutical products.
ESTHER : Liu_2021_Molecules_26_
PubMedSearch : Liu_2021_Molecules_26_
PubMedID: 34771145

Title : [Diagnostic value of combined detection of different indicators for type 2 diabetes mellitus combined with atherosclerotic disease] - Jiang_2021_Zhonghua.Yi.Xue.Za.Zhi_101_2448
Author(s) : Jiang WW , Niu JD , Qi MJ , Song YW , Dang YQ , Yang PQ , Yang J , Liu YM
Ref : Zhonghua Yi Xue Za Zhi , 101 :2448 , 2021
Abstract : Objective: To investigate the diagnostic value of serum lipoprotein associated phospholipase A2 (Lp-PLA2), amyloid A (SAA) and immunoglobulin E (IgE) in patients with type 2 diabetes (T2DM) mellitus complicated with atherosclerotic disease. Methods: From June to December 2019, 224 patients with T2DM in the Second Hospital of Lanzhou University were selected, including 144 males and 80 females, aged (61+/-11) years. According to the results of imaging examination, the patients were divided into T2DM with AS group (T2DM-AS group, n=160) and T2DM group (n=64); Healthy subjects in the same period were selected as healthy control group (n=160). Lp-PLA2, IgE, SAA, hs-CRP, TC, TG, HDL-C, LDL-C and Hcy were detected in all patients and healthy controls. The correlation between the above indexes, gender, age and T2DM with AS was analyzed; Multivariate logistic regression was used to analyze the risk factors of T2DM with AS. Results: Compared with the healthy control group, the levels of IgE and Lp-PLA2 in T2DM-AS group and T2DM group were increased, and the levels of SAA in T2DM-AS group were increased (all P<0.05); Compared with T2DM group, the levels of Lp-PLA2, IgE and SAA were increased in T2DM-AS group (all P<0.05). T2DM with AS was positively correlated with age, IgE, Lp-PLA2 and SAA (r=0.468, 0.269, 0.486, 0.418, all P<0.05), and negatively correlated with HDL-C (r=-0.338, P<0.05). Multivariate logistic regression analysis showed that age (OR=0.865, 95%CI: 0.763-0.982, P<0.05), IgE (OR=0.910, 95%CI: 0.840-0.987, P<0.05) and Lp-PLA2 (OR=0.942, 95%CI: 0.910-0.986, P<0.05) were risk factors of T2DM with AS. ROC curve showed that the combined detection of Lp-PLA2, SAA and IgE could improve the diagnostic efficiency of T2DM with AS (AUC=0.895, P<0.05), the sensitivity was 80.0%, and the specificity was 93.7%. Conclusion: The levels of Lp-PLA2, IgE and SAA increase in T2DM patients with AS. The combined detection of Lp-PLA2, SAA and IgE can improve the diagnostic efficiency of T2DM patients with AS.
ESTHER : Jiang_2021_Zhonghua.Yi.Xue.Za.Zhi_101_2448
PubMedSearch : Jiang_2021_Zhonghua.Yi.Xue.Za.Zhi_101_2448
PubMedID: 34399558

Title : No significant association between dipeptidyl peptidase-4 inhibitors and adverse outcomes of COVID-19 - Zhou_2020_World.J.Clin.Cases_8_5576
Author(s) : Zhou JH , Wu B , Wang WX , Lei F , Cheng X , Qin JJ , Cai JJ , Zhang XJ , Zhou F , Liu YM , Li HM , Zhu LH , She ZG , Zhang X , Yang J , Li HL
Ref : World J Clin Cases , 8 :5576 , 2020
Abstract : BACKGROUND: Dipeptidyl peptidase-4 (DPP4) is commonly targeted to achieve glycemic control and has potent anti-inflammatory and immunoregulatory effects. Recent structural analyses indicated a potential tight interaction between DPP4 and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), raising a promising hypothesis that DPP4 inhibitor (DPP4i) drugs might be an optimal strategy for treating coronavirus disease 2019 (COVID-19) among patients with diabetes. However, there has been no direct clinical evidence illuminating the associations between DPP4i use and COVID-19 outcomes. AIM: To illuminate the associations between DPP4i usage and the adverse outcomes of COVID-19. METHODS: We conducted a multicenter, retrospective analysis including 2563 patients with type 2 diabetes who were hospitalized due to COVID-19 at 16 hospitals in Hubei Province, China. After excluding ineligible individuals, 142 patients who received DPP4i drugs and 1115 patients who received non-DPP4i oral anti-diabetic drugs were included in the subsequent analysis. We performed a strict propensity score matching (PSM) analysis where age, sex, comorbidities, number of oral hypoglycemic agents, heart rate, blood pressure, pulse oxygen saturation (SpO(2)) < 95%, CT diagnosed bilateral lung lesions, laboratory indicators, and proportion of insulin usage were matched. Finally, 111 participants treated with DPP4i drugs were successfully matched to 333 non-DPP4i users. Then, a linear logistic model and mixed-effect Cox model were applied to analyze the associations between in-hospital DPP4i use and adverse outcomes of COVID-19. RESULTS: After rigorous matching and further adjustments for imbalanced variables in the linear logistic model and Cox adjusted model, we found that there was no significant association between in-hospital DPP4i use (DPP4i group) and 28-d all-cause mortality (adjusted hazard ratio = 0.44, 95%CI: 0.09-2.11, P = 0.31). Likewise, the incidences and risks of secondary outcomes, including septic shock, acute respiratory distress syndrome, or acute organ (kidney, liver, and cardiac) injuries, were also comparable between the DPP4i and non-DPP4i groups. The performance of DPP4i agents in achieving glucose control (e.g., the median level of fasting blood glucose and random blood glucose) and inflammatory regulation was approximately equivalent in the DPP4i and non-DPP4i groups. Furthermore, we did not observe substantial side effects such as uncontrolled glycemia or acidosis due to DPP4i application relative to the use of non-DPP4i agents in the study cohort. CONCLUSION: Our findings demonstrated that DPP4i use is not significantly associated with poor outcomes of COVID-19 or other adverse effects of anti-diabetic treatment. The data support the continuation of DPP4i agents for diabetes management in the setting of COVID-19.
ESTHER : Zhou_2020_World.J.Clin.Cases_8_5576
PubMedSearch : Zhou_2020_World.J.Clin.Cases_8_5576
PubMedID: 33344548

Title : New 4-N-phenylaminoquinoline derivatives as antioxidant, metal chelating and cholinesterase inhibitors for Alzheimer's disease - Cai_2019_Bioorg.Chem_93_103328
Author(s) : Cai R , Wang LN , Fan JJ , Geng SQ , Liu YM
Ref : Bioorg Chem , 93 :103328 , 2019
Abstract : A series of new 4-N-phenylaminoquinoline derivatives were designed, synthesized, and their anticholinesterase activities, 1,1-Diphenyl-2-picrylhydrazyl (DPPH) radical scavenging activity, metal-chelating ability were tested. Among them, compounds 11j, 11k and 11l had comparable inhibition activities to reference drug galantamine both in AChE and in BChE. Especially, compound 11j revealed the most potent inhibition to eeAChE and eqBChE with IC50 values of 1.20muM and 18.52muM, respectively. Furthermore, both kinetic analysis of AChE inhibition and molecular docking study indicated that compound 11j was mixed-type inhibitor, binding simultaneously to the catalytic anionic site (CAS) and the peripheral anionic site (PAS) of AChE, and propidium iodide displacement assay showed significant displacement of propidium iodide with compound 11k (25.80%) from PAS of eeAChE. More importantly, compound 11l displayed excellent DPPH radical scavenging activity (84% at 1mg/mL), and its EC50 value was 0.328muM. In addition, compounds 11a, 11j, 11k and 11l exhibited obvious biometal chelating abilities toward Al(3+), Fe(2+), Cu(2+) and Zn(2+) ions. Taken together, 4-N-phenylaminoquinoline derivatives targeting multiple pathogenetic factors deserve further investigation for treatment of AD.
ESTHER : Cai_2019_Bioorg.Chem_93_103328
PubMedSearch : Cai_2019_Bioorg.Chem_93_103328
PubMedID: 31600664

Title : Design, synthesis, evaluation and molecular modeling study of 4-N-phenylaminoquinolines for Alzheimer disease treatment - Zhu_2019_Bioorg.Med.Chem.Lett_29_1325
Author(s) : Zhu J , Wang LN , Cai R , Geng SQ , Dong YF , Liu YM
Ref : Bioorganic & Medicinal Chemistry Lett , 29 :1325 , 2019
Abstract : Dual binding site acetylcholinesterase (AChE) inhibitors and butyrylcholinesterase (BChE) inhibitors have recently emerged as two classes of new anti-Alzheimer agents to positively modify the disease's course. In this work, a new series of 4-N-phenylaminoquinolines was synthesized and evaluated for their abilities to inhibit AChE and BChE. Compound 11b showed significant inhibitory activities on AChE and BChE with IC50 values of 0.86 and 2.65muM, respectively, a lot better than that of reference drug galanthamine. Furthermore, docking study showed that compound 11b interacted simultaneously not only with active and peripheral sites of AChE, but also with all five regions of BChE active site. These findings suggest that these derivatives could be regarded as promising starting points for further drug discovery developments.
ESTHER : Zhu_2019_Bioorg.Med.Chem.Lett_29_1325
PubMedSearch : Zhu_2019_Bioorg.Med.Chem.Lett_29_1325
PubMedID: 30956012

Title : Isosteroidal alkaloids as potent dual-binding site inhibitors of both acetylcholinesterase and butyrylcholinesterase from the bulbs of Fritillaria walujewii - Liu_2017_Eur.J.Med.Chem_137_280
Author(s) : Liu YM , Feng YD , Lu X , Nie JB , Li W , Wang LN , Tian LJ , Liu QH
Ref : Eur Journal of Medicinal Chemistry , 137 :280 , 2017
Abstract : Five new isosteroidal alkaloids, walujewine A (1), walujewine B (4), walujewine C (5), walujewine D (6), walujewine E (10) were isolated from the bulbs of Fritillaria walujewii together with seven known isosteroidal alkaloids (2, 3, 7-9, 11, 12). Their structures were elucidated on the basis of IR, ESI-MS, HR-ESI-MS, 1D and 2D NMR spectroscopic data analyses and single-crystal X-ray diffraction. All the isolates were tested for ChE inhibiting activity by the Ellman's method. Compounds 3-5 and 8-10 were potent dual AChE-BChE inhibitors, and compound 1 showed highly selective AChE inhibition. The structure-activity relationship of compounds 1-12 was discussed in details. And kinetic analysis showed that compounds 1, 3-5, and 8-10 were mixed-type reversible inhibitors of AChE, simultaneously binding to the catalytic and peripheral anionic sites, which was verified by in silico docking studies. The docking simulation also showed that active compound 3 and 8 created many interactions with the CAS and PAS gorges of BChE, revealing their mixed-type inhibition. ADMET analysis further confirmed the therapeutic potential of some isosteroidal alkaloids based on their high BBB-penetration.
ESTHER : Liu_2017_Eur.J.Med.Chem_137_280
PubMedSearch : Liu_2017_Eur.J.Med.Chem_137_280
PubMedID: 28605675

Title : Single and Multiple Dose Pharmacokinetics, Pharmacodynamics and Safety of the Novel Lipoprotein-Associated Phospholipase A2 Enzyme Inhibitor Darapladib in Healthy Chinese Subjects: An Open Label Phase-1 Clinical Trial - Hu_2015_PLoS.One_10_e0139862
Author(s) : Hu C , Tompson D , Magee M , Chen Q , Liu YM , Zhu W , Zhao H , Gross AS , Liu Y
Ref : PLoS ONE , 10 :e0139862 , 2015
Abstract : BACKGROUND AND OBJECTIVES: Darapladib is a lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitor. This study evaluated the pharmacokinetics, pharmacodynamics and safety of darapladib in healthy Chinese subjects.
METHODS: Twenty-four subjects received darapladib 160 mg orally, approximately 1 hour after a standard breakfast, as a single dose and once daily for 28 days. Non-compartmental methods were used to determine the single and multiple dose pharmacokinetics of darapladib and its metabolite SB-553253. Repeat dose Lp-PLA2 activity and safety were evaluated.
RESULTS: Systemic exposure (AUC(0-T), Cmax geometric mean (CVb%)) of darapladib was higher after multiple-dosing (519 ng.h/mL (33.3%), 34.4 ng/mL (49.9%)) compared to single-dose administration (153 ng.h/mL (69.0%), 17.9 ng/mL (55.2%). The steady-state accumulation ratio was less than unity (Rs = 0.80), indicating time-dependent pharmacokinetics of darapladib. Darapladib steady-state was reached by Day 14 of once daily dosing. Systemic exposure to SB-553253 was lower than darapladib with median (SB-553253: darapladib) ratios for AUC(0-tau) of 0.0786 for single dose and 0.0532 for multiple dose administration. On Day 28, pre-dose and maximum inhibition of Lp-PLA2 activity was approximately 70% and 75% relative to the baseline value, respectively and was dependent of darapladib concentration. The most common adverse events (>/= 21% subjects) were abnormal faeces, abnormal urine odour, diarrhoea and nasopharyngitis. CONCLUSION: Darapladib 160 mg single and repeat doses were profiled in healthy Chinese subjects. Single dose systemic exposure to darapladib in healthy Chinese subjects was consistent with that observed previously in Western subjects whereas steady-state systemic exposure was approximately 65% higher in Chinese than Western subjects. The Lp-PLA2 activity and adverse event profile were similar in healthy Chinese and previous reports in Western subjects. Ethnic-specific dose adjustment of darapladib is not considered necessary for the Chinese population. TRIAL REGISTRATION: ClinicalTrials.gov NCT02000804.
ESTHER : Hu_2015_PLoS.One_10_e0139862
PubMedSearch : Hu_2015_PLoS.One_10_e0139862
PubMedID: 26465780

Title : Fast identification of lipase inhibitors in oolong tea by using lipase functionalised Fe3O4 magnetic nanoparticles coupled with UPLC-MS\/MS - Zhu_2015_Food.Chem_173_521
Author(s) : Zhu YT , Ren XY , Yuan L , Liu YM , Liang J , Liao X
Ref : Food Chem , 173 :521 , 2015
Abstract : Oolong tea is an important member in tea family, which claims for various health benefits such as preventing obesity and improving lipid metabolism. In this work, using pancreatic lipase (PL) functionalised magnetic nanoparticles (PL-MNPs) as solid phase extraction absorbent in combination with ultra-high performance liquid chromatography-mass spectrometry (UPLC-MS), we developed a method for rapid screening and identification of lipase inhibitors from oolong tea. Three PL ligands were selectively extracted and identified as (-)-epigallocatechin-3-O-gallate (EGCG), (-)-gallocatechin-3-O-gallate (GCG) and (-)-epicatechin-3-O-gallate (ECG). Their lipase inhibitory activities were significantly higher than those non-ligands. Structure-activity analysis revealed that the presence of a galloyl moiety in the structure was required for binding to PL-MNPs, and therefore, exhibiting a strong inhibition on the enzyme. Taking advantages of the specificity in enzyme binding and the convenience of magnetic separation, this method has great potential for fast screening of lipase inhibitors from natural resources.
ESTHER : Zhu_2015_Food.Chem_173_521
PubMedSearch : Zhu_2015_Food.Chem_173_521
PubMedID: 25466054

Title : Covalent immobilization of porcine pancreatic lipase on carboxyl-activated magnetic nanoparticles: Characterization and application for enzymatic inhibition assays - Zhu_2014_Mater.Sci.Eng.C.Mater.Biol.Appl_38_278
Author(s) : Zhu YT , Ren XY , Liu YM , Wei Y , Qing LS , Liao X
Ref : Mater Sci Eng C Mater Biol Appl , 38 :278 , 2014
Abstract : Using carboxyl functionalized silica-coated magnetic nanoparticles (MNPs) as carrier, a novel immobilized porcine pancreatic lipase (PPL) was prepared through the 1-ethyl-3-[3-dimethylaminopropyl] carbodiimide hydrochloride/N-hydroxysuccinimide (EDC/NHS) coupling reaction. Transmission electron microscopic images showed that the synthesized nanoparticles (Fe3O4-SiO2) possessed three dimensional core-shell structures with an average diameter of ~20nm. The effective enzyme immobilization onto the nanocomposite was confirmed by atomic force microscopic (AFM) analysis. Results from Fourier-transform infrared spectroscopy (FT-IR), Bradford protein assay, and thermo-gravimetric analysis (TGA) indicated that PPL was covalently attached to the surface of magnetic nanoparticles with a PPL immobilization yield of 50mg enzyme/g MNPs. Vibrating sample magnetometer (VSM) analysis revealed that the MNPs-PPL nanocomposite had a high saturation magnetization of 42.25emu.g(-1). The properties of the immobilized PPL were investigated in comparison with the free enzyme counterpart. Enzymatic activity, reusability, thermo-stability, and storage stability of the immobilized PPL were found significantly superior to those of the free one. The Km and the Vmax values (0.02mM, 6.40U.mg(-1) enzyme) indicated the enhanced activity of the immobilized PPL compared to those of the free enzyme (0.29mM, 3.16U.mg(-1) enzyme). Furthermore, at an elevated temperature of 70 degrees C, immobilized PPL retained 60% of its initial activity. The PPL-MNPs nanocomposite was applied in the enzyme inhibition assays using orlistat, and two natural products isolated from oolong tea (i.e., EGCG and EGC) as the test compounds.
ESTHER : Zhu_2014_Mater.Sci.Eng.C.Mater.Biol.Appl_38_278
PubMedSearch : Zhu_2014_Mater.Sci.Eng.C.Mater.Biol.Appl_38_278
PubMedID: 24656379

Title : Complete genome sequence of Klebsiella oxytoca E718, a New Delhi metallo-beta-lactamase-1-producing nosocomial strain - Liao_2012_J.Bacteriol_194_5454
Author(s) : Liao TL , Lin AC , Chen E , Huang TW , Liu YM , Chang YH , Lai JF , Lauderdale TL , Wang JT , Chang SC , Tsai SF , Chen YT
Ref : Journal of Bacteriology , 194 :5454 , 2012
Abstract : We report the complete genome sequence of Klebsiella oxytoca E718, a New Delhi metallo-beta-lactamase-1 (NDM-1)-producing strain isolated from a renal transplant patient. The genome contains a 6,097,032-bp chromosome and two multidrug resistance plasmids with sizes of 324,906 bp and 110,781 bp.
ESTHER : Liao_2012_J.Bacteriol_194_5454
PubMedSearch : Liao_2012_J.Bacteriol_194_5454
PubMedID: 22965083
Gene_locus related to this paper: kleox-h3l7b3 , klep7-y1077 , kleox-z5vsa8 , kleox-v3ks46

Title : Sequencing and comparative genome analysis of two pathogenic Streptococcus gallolyticus subspecies: genome plasticity, adaptation and virulence - Lin_2011_PLoS.One_6_e20519
Author(s) : Lin IH , Liu TT , Teng YT , Wu HL , Liu YM , Wu KM , Chang CH , Hsu MT
Ref : PLoS ONE , 6 :e20519 , 2011
Abstract : Streptococcus gallolyticus infections in humans are often associated with bacteremia, infective endocarditis and colon cancers. The disease manifestations are different depending on the subspecies of S. gallolyticus causing the infection. Here, we present the complete genomes of S. gallolyticus ATCC 43143 (biotype I) and S. pasteurianus ATCC 43144 (biotype II.2). The genomic differences between the two biotypes were characterized with comparative genomic analyses. The chromosome of ATCC 43143 and ATCC 43144 are 2,36 and 2,10 Mb in length and encode 2246 and 1869 CDS respectively. The organization and genomic contents of both genomes were most similar to the recently published S. gallolyticus UCN34, where 2073 (92%) and 1607 (86%) of the ATCC 43143 and ATCC 43144 CDS were conserved in UCN34 respectively. There are around 600 CDS conserved in all Streptococcus genomes, indicating the Streptococcus genus has a small core-genome (constitute around 30% of total CDS) and substantial evolutionary plasticity. We identified eight and five regions of genome plasticity in ATCC 43143 and ATCC 43144 respectively. Within these regions, several proteins were recognized to contribute to the fitness and virulence of each of the two subspecies. We have also predicted putative cell-surface associated proteins that could play a role in adherence to host tissues, leading to persistent infections causing sub-acute and chronic diseases in humans. This study showed evidence that the S. gallolyticus still possesses genes making it suitable in a rumen environment, whereas the ability for S. pasteurianus to live in rumen is reduced. The genome heterogeneity and genetic diversity among the two biotypes, especially membrane and lipoproteins, most likely contribute to the differences in the pathogenesis of the two S. gallolyticus biotypes and the type of disease an infected patient eventually develops.
ESTHER : Lin_2011_PLoS.One_6_e20519
PubMedSearch : Lin_2011_PLoS.One_6_e20519
PubMedID: 21633709
Gene_locus related to this paper: strei-e0pe09 , strg3-d3hd15 , strg3-d3hey7

Title : Genome sequencing and comparative analysis of Klebsiella pneumoniae NTUH-K2044, a strain causing liver abscess and meningitis - Wu_2009_J.Bacteriol_191_4492
Author(s) : Wu KM , Li LH , Yan JJ , Tsao N , Liao TL , Tsai HC , Fung CP , Chen HJ , Liu YM , Wang JT , Fang CT , Chang SC , Shu HY , Liu TT , Chen YT , Shiau YR , Lauderdale TL , Su IJ , Kirby R , Tsai SF
Ref : Journal of Bacteriology , 191 :4492 , 2009
Abstract : Nosocomial infections caused by antibiotic-resistant Klebsiella pneumoniae are emerging as a major health problem worldwide, while community-acquired K. pneumoniae infections present with a range of diverse clinical pictures in different geographic areas. In particular, an invasive form of K. pneumoniae that causes liver abscesses was first observed in Asia and then was found worldwide. We are interested in how differences in gene content of the same species result in different diseases. Thus, we sequenced the whole genome of K. pneumoniae NTUH-K2044, which was isolated from a patient with liver abscess and meningitis, and analyzed differences compared to strain MGH 78578, which was isolated from a patient with pneumonia. Six major types of differences were found in gene clusters that included an integrative and conjugative element, clusters involved in citrate fermentation, lipopolysaccharide synthesis, and capsular polysaccharide synthesis, phage-related insertions, and a cluster containing fimbria-related genes. We also conducted comparative genomic hybridization with 15 K. pneumoniae isolates obtained from community-acquired or nosocomial infections using tiling probes for the NTUH-K2044 genome. Hierarchical clustering revealed three major groups of genomic insertion-deletion patterns that correlate with the strains' clinical features, antimicrobial susceptibilities, and virulence phenotypes with mice. Here we report the whole-genome sequence of K. pneumoniae NTUH-K2044 and describe evidence showing significant genomic diversity and sequence acquisition among K. pneumoniae pathogenic strains. Our findings support the hypothesis that these factors are responsible for the changes that have occurred in the disease profile over time.
ESTHER : Wu_2009_J.Bacteriol_191_4492
PubMedSearch : Wu_2009_J.Bacteriol_191_4492
PubMedID: 19447910
Gene_locus related to this paper: klep3-b5xzn5 , klep3-b5xzy8 , klep3-bioh , klep7-a6t8q2 , klep7-a6tb98 , klep7-a6tbn9 , klep7-menh , klep7-mhpc , klep7-y243 , klep7-y1077 , klepn-c4x8c8 , klepn-c4x8h0 , klepn-c4x8q1 , klepn-q6u5x9 , klepn-w8uta0

Title : Comparative genome analysis of Vibrio vulnificus, a marine pathogen - Chen_2003_Genome.Res_13_2577
Author(s) : Chen CY , Wu KM , Chang YC , Chang CH , Tsai HC , Liao TL , Liu YM , Chen HJ , Shen AB , Li JC , Su TL , Shao CP , Lee CT , Hor LI , Tsai SF
Ref : Genome Res , 13 :2577 , 2003
Abstract : The halophile Vibrio vulnificus is an etiologic agent of human mortality from seafood-borne infections. We applied whole-genome sequencing and comparative analysis to investigate the evolution of this pathogen. The genome of biotype 1 strain, V. vulnificus YJ016, was sequenced and includes two chromosomes of estimated 3377 kbp and 1857 kbp in size, and a plasmid of 48,508 bp. A super-integron (SI) was identified, and the SI region spans 139 kbp and contains 188 gene cassettes. In contrast to non-SI sequences, the captured gene cassettes are unique for any given Vibrio species and are highly variable among V. vulnificus strains. Multiple rearrangements were found when comparing the 5.3-Mbp V. vulnificus YJ016 genome and the 4.0-Mbp V. cholerae El Tor N16961 genome. The organization of gene clusters of capsular polysaccharide, iron metabolism, and RTX toxin showed distinct genetic features of V. vulnificus and V. cholerae. The content of the V. vulnificus genome contained gene duplications and evidence of horizontal transfer, allowing for genetic diversity and function in the marine environment. The genomic information obtained in this study can be applied to monitoring vibrio infections and identifying virulence genes in V. vulnificus.
ESTHER : Chen_2003_Genome.Res_13_2577
PubMedSearch : Chen_2003_Genome.Res_13_2577
PubMedID: 14656965
Gene_locus related to this paper: vibch-rtxAABH , vibvu-VV10137 , vibvu-VV10171 , vibvu-VV10305 , vibvu-VV10607 , vibvu-VV10627 , vibvu-VV10862 , vibvu-VV11137 , vibvu-VV11321 , vibvu-VV12133 , vibvu-VV12349 , vibvu-VV13171 , vibvu-VV20101 , vibvu-VV20395 , vibvu-VV20739 , vibvu-VV20795 , vibvu-VV20967 , vibvu-VV20970 , vibvu-VV21216 , vibvu-yk72 , vibvy-q7mff9 , vibvy-q7mfv5 , vibvy-q7mn77 , vibvy-y856